However, GLP-1 antagonists and GLP-1 agonists work differently: GLP-1 agonists (like Ozempic and Wegovy) mimic the GLP-1 hormone, activating its receptors to increase insulin release, suppress appetite, and slow digestion
Randomized controlled trials (RCTs) have shown that, compared to BI, GLP-1RA granted similar or greater HbA1c reductions, but with lower rates of hypoglycemia, substantial weight loss, and easier administration schedule [4]
Standard Dosing Range Most users find therapeutic benefit with daily doses between 0.25mg and 0.5mg
Progressive overload, meaning you gradually increase the weight, reps, or difficulty over time
No GLP-1 receptor agonist currently holds FDA approval for the treatment of binge eating disorder
In cases of concern, contacting Poison Control (1-800-222-1222) can provide additional guidance